TGI-17a (Hefei TG ImmunoPharma)

TGI-17a (Hefei TG ImmunoPharma): sourced facts only. name: "TGI-17a exhibited intermediate affinity for IL-2Rα (KD = 19.2 nM), while its affinity for IL-2Rβγ was over 50-fold lower (KD = 1060 nM), rendering it a more profoundly IL-2Rα-biased molecule compared to the competitor." [DOI:10.1158/1538-7445.am2026-4336]; target: "TGI-17a exhibited intermediate affinity for IL-2Rα (KD = 19.2 nM), while its affinity for IL-2Rβγ was over 50-fold lower (KD = 1060 nM), rendering it a more profoundly IL-2Rα-biased molecule compared to the competitor." [DOI:10.1158/1538-7445.am2026-4336]; developer: "Hefei TG ImmunoPharma Co., Ltd., Hefei, China." [DOI:10.1158/1538-7445.am2026-4336]; modality: "TGI-17a is a potential best-in-class PD-1/IL-2α-bias bispecific antibody designed to specifically activate antigen-specific CD8+T cells by synergistically blocking inhibitory PD-1 signaling while enhancing activating IL-2 signaling." [DOI:10.1158/1538-7445.am2026-4336]; stage: "The anti-tumor efficacy of TGI-17a was investigated in MC38 and B16F10 syngeneic tumor models using humanized PD-1 transgenic mice." [DOI:10.1158/1538-7445.am2026-4336]